Causal factors for brain tumor and targeted strategies

Springer Proceedings in Physics

Volumn 150, Issue , 2014, Pages 191-204

  Debata, Priya Ranjan ^a   Curcio, Gina Marie ^a   Mukherjee, Sumit ^a   Banerjee, Probal ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; DISEASE CONTROL; INVESTMENTS; MOLECULAR BIOLOGY; NANOTECHNOLOGY; TUMORS;

ANTI-CANCER AGENTS; CANCER PATIENTS; FIVE-YEAR PLANS; GENETIC DISEASE; NATURAL PRODUCTS; PERSONALIZED MEDICINES; PRIMARY BRAIN TUMORS; THERAPEUTIC STRATEGY;

DISEASES;

EID: 84943237167     PISSN: 09308989     EISSN: 18674941     Source Type: Conference Proceeding    
DOI: 10.1007/978-3-319-02207-9_19     Document Type: Conference Paper

References (96)

1. J.E. Wolff et al., Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatr. Blood Cancer 59(1), 27–33 (2012)
2. E.C. Peterson et al., Radiation-induced complications in endovascular neurosurgery: incidence of skin effects and the feasibility of estimating risk of future tumor formation. Neurosurgery (2012)
3. M.Z. Braganza et al., Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro-Oncol. 14(11), 1316–1324 (2012)
4. K. Hemminki et al., Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol. 10(5), 481–488 (2009)
5. T. Brown et al., Occupational cancer in Britain. Remaining cancer sites: brain, bone, soft tissue sarcoma and thyroid. Br. J. Cancer 107(1), 85–91 (2012)
6. J.S. Nelson et al., Potential risk factors for incident glioblastoma multiforme: the Honolulu heart program and Honolulu-Asia aging study. J. Neurooncol. 109(2), 315–321 (2012)
7. K. Alibek, A. Kakpenova, Y. Baiken, Role of infectious agents in the carcinogenesis of brain and head and neck cancers. Infect. Agents Cancer 8(1), 7 (2013)
8. S. Cordier et al., Incidence and risk factors for childhood brain tumors in the Ile de France. Int. J. Cancer 59(6), 776–782 (1994)
9. J.M. Pogoda et al., An international case-control study of maternal diet during pregnancy and childhood brain tumor risk: a histology-specific analysis by food group. Ann. Epidemiol. 19(3), 148–160 (2009)
10. H. Ohgaki, P. Kleihues, Epidemiology and etiology of gliomas. Acta Neuropathol. 109, 93–108 (2005)
11. O. Warburg, On the origin of cancer cells. Science 123, 309–314 (1956)
12. F. Pistollata, H.-L. Chen, B.R. Rood, H.-Z. Zhang, D. D’Avella, L. Denaro, M. Gardiman, G. Te Kronnie, P.H. Schwartz, E. Favaro, S. Indraccolo, G. Basso, D.M. Panchision, Hypoxia and HIF1alpha repress the differentiative effects of BMPs in high-grade glioma. Cancer Stem Cells 27, 7–17 (2009)
13. H. Ramsahye et al., Central neurocytoma: radiological and clinico-pathological findings in 18 patients and one additional MRS case. J. Neuroradiol. (2013)
14. P.Y. Wen, S. Kesari, Malignant gliomas in adults. N. Engl. J. Med. 359(5), 492–507 (2008)
15. J. Chen et al., A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412), 522–526 (2012)
16. FDA Approval for Temozolomide, National Cancer Institute (2010). http://www.cancer.gov/cancertopics/druginfo/fda-temozolomide
17. L. Ricci-Vitiani et al., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325), 824–828 (2010)
18. R. Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005)
19. A.K. Anand et al., Survival outcome and neurotoxicity in patients of high-grade gliomas treated with conformal radiation and temozolamide. J. Cancer Res. Ther. 8(1), 50–56 (2012)
20. S. Sahebjam et al., Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. Can. J. Neurol. Sci. 40(2), 241–246 (2013)
21. F.B. Furnari et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683–2710 (2007)
22. B.E. Stopschinski, C.P. Beier, D. Beier, Glioblastoma cancer stem cells—from concept to clinical application. Cancer Lett. 338, 32–40 (2013)
23. B.S. Malmer et al., Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J. Neurooncol. 82(3), 229–237 (2007)
24. L.E. Wang et al., Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 64(16), 5560–5563 (2004)
25. D.A. Haas-Kogan et al., p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int. J. Radiat. Oncol. Biol. Phys. 43(2), 399–403 (1999)
26. I. Zawlik et al., Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol. 19(2), 188–194 (2009)
27. S.E. Yost et al., High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. PLoS ONE 8(2), e56185 (2013)
28. L. Bethke et al., The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol. Biomark. Prev. 17(4), 987–989 (2008)
29. A. Wigertz et al., Allergic conditions and brain tumor risk. Am. J. Epidemiol. 166(8), 941–950 (2007)
30. K. Ueki et al., CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56(1), 150–153 (1996)
31. K. Ichimura et al., Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22(1), 9–15 (1998)
32. W. Biernat et al., Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 94(4), 303–309 (1997)
33. S. Pfister et al., BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 118(5), 1739–1749 (2008)
34. D.T. Jones et al., Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68(21), 8673–8677 (2008)
35. A. Kaul et al., Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev. 26(23), 2561–2566 (2012)
36. C. Wibom et al., EGFR gene variants are associated with specific somatic aberrations in glioma. PLoS ONE 7(12), 47929 (2012)
37. B.M. Costa et al., Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol. Biomark. Prev. 20(12), 2610–2617 (2011)
38. S. Jeon et al., Genetic variants of AICDA/CASP14 associated with childhood brain tumor. Genet. Mol. Res. 12(AOP) (2013)
39. V.E. Clark et al., Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123), 1077–1080 (2013)
40. L.M. Dyer, K.P. Schooler, L. Ai, C. Klop, J. Qiu, K.D. Robertson, D. Kevin, The transglutaminase 2 gene is aberrantly hypermethylated in glioma. J. Neurooncol. 101(3), 429 (2010)
41. A. Restrepo et al., Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. Neuro-Oncol. 13(1), 42–50 (2011)
42. C. Piperi et al., High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol. Med. 16(1–2), 1–9 (2010)
43. S.A. Kim et al., Promoter methylation of WNT inhibitory factor-1 and expression pattern of WNT/beta-catenin pathway in human astrocytoma: pathologic and prognostic correlations. Mod. Pathol. (2013)
44. N. Syed et al., Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis. 4, 458 (2013)
45. P. Vaitkiene et al., GATA4 and DcR1 methylation in glioblastomas. Diagn. Pathol. 8(1), 7 (2013)
46. M. Martini et al., Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer 119(5), 1004–1012 (2013)
47. A.P. Chou et al., Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J. Natl. Cancer Inst. 104(19), 1458–1469 (2012)
48. A. von dem Knesebeck et al., RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. Neoplasia 14(6), 526–534 (2012)
49. D. Skiriute et al., MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer 12, 218 (2012)
50. A. Waha et al., Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas. Int. J. Cancer 131(3), 612–622 (2012)
51. M. Kadowaki et al., DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int. J. Cancer 130(2), 267–277 (2012)
52. M. Wetzel et al., Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J. Neurosurg. 103(6), 549–556 (2005)
53. A. Bangert et al., Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anticancer Drugs 22(6), 494–499 (2011)
54. A. Bangert et al., Histone deacetylase inhibitors sensitize glioblastoma cells to TRAILinduced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 31(44), 4677–4688 (2012)
55. S. Hacker et al., Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 30(19), 2275–2281 (2011)
56. R.A. Gatenby, R.J. Gillies, Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4(11), 891–899 (2004)
57. R.J. DeBerardinis et al., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 7(1), 11–20 (2008)
58. D. Hanahan, R.A. Weinberg, The hallmarks of cancer. Cell 100(1), 57–70 (2000)
59. D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011)
60. A. Ramanathan, C. Wang, S.L. Schreiber, Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. 102(17), 5992–5997 (2005)
61. I. Marin-Valencia et al., Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metabolism 15(6), 827–837 (2012)
62. T.N. Seyfried, L.M. Shelton, P. Mukherjee, Does the existing standard of care increase glioblastoma energy metabolism? Lancet Oncol. 11, 811–813 (2010)
63. T.N. Seyfried, L.M. Shelton, Cancer as a metabolic disease. Nutr. Metab. 7, 7 (2010)
64. T.N. Seyfried, M.A. Kiebish, J. Marsh, L.M. Shelton, L.C. Huysentruyt, P. Mukherjee, Metabolic management of brain cancer. Biochim. Biophys. Acta 1807, 577–594 (2011)
65. E.A. Maher et al., Metabolism of [U-13C] glucose in human brain tumors in vivo. NMR Biomed. 25(11), 1234–1244 (2012)
66. E.A. Maher, F.B. Furnari, R.M. Bachoo, D.H. Rowitch, D.N. Louis, W.K. Cavenee, R.A. DePinho, Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15, 1311–1333 (2001)
67. K.M. Egan et al., Cancer susceptibility variants and the risk of adult glioma in a US casecontrol study. J. Neurooncol. 104(2), 535–542 (2011)
68. D. Hanahan, R.A. Weinberg, In search of cancer’s common ground: a next-generation view. ScienceDaily (2011). http://www.sciencedaily.com/releases/2011/03/110303132300.htm
69. A. Carter, Curry compound fights cancer in the clinic. J. Natl. Cancer Inst. 100, 616–617 (2008)
70. J. Ravindran, S. Prasad, B.B. Aggarwal, Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 11, 495–510 (2009)
71. W.-Y. Huang, Y.-Z. Cai, Y. Zhang, Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr. Cancer 62(1), 1–20 (2009)
72. S. Purkayastha et al., Curcumin blocks brain tumor formation. Brain Res. (2009)
73. S. Shishodia, G. Sethi, B.B. Aggarwal, Curcumin: getting back to the roots. Ann. N.Y. Acad. Sci. 1056(1), 206–217 (2005)
74. J. Weissenberger et al., Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin. Cancer Res. 16(23), 5781–5795 (2010)
75. W. Zhuang et al., Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy. Cancer Sci. 103(4), 684–690 (2012)
76. C. Senft et al., The nontoxic natural compound Curcumin exerts anti-proliferative, antimigratory, and anti-invasive properties against malignant gliomas. BMC Cancer 10, 491 (2010)
77. T.Y. Huang et al., Curcuminoids suppress the growth and induce apoptosis through caspase- 3-dependent pathways in glioblastoma multiforme (GBM) 8401 cells. J. Agric. Food Chem. 58(19), 10639–10645 (2010)
78. M.C. Perry et al., Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol. Nutr. Food Res. 54(8), 1192–1201 (2010)
79. S. Karmakar, N.L. Banik, S.K. Ray, Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells. Neurochem. Res. 32(12), 2103–2113 (2007)
80. A.K. Khaw et al., Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells. J. Cell Biochem. (2012)
81. A. Goel, S. Jhurani, B.B. Aggarwal, Multi-targeted therapy by curcumin: how spicy is it? Mol. Nutr. Food Res. 52, 1010–1030 (2008)
82. P. Langone, G.M. Curcio, K. Kashfi, S. Dolai, K. Raja, P. Banerjee, Drug targeting to eliminate breast and brain tumors, in Joint AACR and ACS Meeting—Chemistry in Cancer Research: The Biological Chemistry of Inflammation as a Cause of Cancer, San Diego, CA (2011)
83. S.J. Lee et al., Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 11, 144 (2011)
84. S.K. Kang, S.H. Cha, H.G. Jeon, Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 15(2), 165–174 (2006)
85. J. Kang et al., Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem. Pharmacol. 69(8), 1205–1213 (2005)
86. K. Balasubramanyam et al., Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279(49), 51163–51171 (2004)
87. J. Fang, J. Lu, A. Holmgren, Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280, 25284–25290 (2005)
88. C. Syng-Ai, A.L. Kumari, A. Khar, Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol. Cancer Ther. 3, 1101–1108 (2004)
89. B.B. Aggarwal, B. Sung, Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 30, 85–94 (2009)
90. S. Manju, K. Sreenivasan, Enhanced drug loading on magnetic nanoparticles by layer-by-layer assembly using drug conjugates: blood compatibility evaluation and targeted drug delivery in cancer cells. Langmuir 27(23), 14489–14496 (2011)
91. J. Shao et al., Curcumin delivery by methoxy polyethylene glycol-poly(caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim. Biophys. Sin. (Shanghai) 43(4), 267–274 (2011)
92. P. Langone, P.R. Debata, S. Dolai, G.M. Curcio, J.D. Inigo, K. Raja, P. Banerjee, Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin. Int. J. Cancer 131, E569–E578 (2012)
93. Drug Record: Temozolomide, in Clinical and Research Information on Drug-Induced Liver Injury (2012). NIDDK, http://livertox.nih.gov/Temozolomide.htm#overview
94. T. Takano, J.H. Lin, G. Arcuino, Q. Gao, J. Yang, M. Nedergaard, Glutamata release promotes growth of malignant gliomas. Nat. Med. 7, 1010–1015 (2001)
95. R. Grondin, Z. Zhang, Y. Ai, D.M. Gash, G.A. Gerhardt, Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog. Drug Res. 61, 101–123 (2003)
96. D. Grady, A direct hit of drugs to treat brain cancer (2010). Available from http://www.nytimes.com/2010/11/09/health/09avastin.html